Professional Medical Associations and Their Relationships With Industry: A Proposal for Controlling Conflict of Interest. Journal of the American Medical Association 1.4.2009. Wegweisende Stellungnahme einer US-amerikanischen Expertengruppe - s.a. www.forum-gesundheitspolitik.de
Sniderman, Furberg. Why Guideline-Making Requires Reform, JAMA January 28, 2009
Interessenkonflikte. Gefahr für das ärztliche Urteilsvermögen. Deutsches Ärzteblatt. Heft 30, 3.Oktober, S. A 2098–2100
David Klemperer.Die Industrie kann Patienten nicht objektiv und ergebnisoffen informieren – DNEbM und DGSMP lehnen Pläne der EU-Kommission ab. ZEFQ, Juli 2008
David Klemperer. Interessenkonflikte im Gesundheitswesen. in: Selbsthilfegruppenjahrbuch 2008
Transparency International Deutschland. Transparenzmängel, Korruption und Betrug im deutschen Gesundheitswesen. Kontrolle und Prävention als gesellschaftliche Aufgabe
Fugh-Berman A, Ahari S (2007) Following the Script: How Drug Reps Make Friends and Influence Doctors PLoS Med 4(4): e150 doi:10.1371/journal.pmed.0040150, April 2007
This article, which grew out of conversations between a former drug rep and a physician who researches pharmaceutical marketing, reveals the strategies used by reps to manipulate physician prescribing.
Steinman MA, Harper GM, Chren MM, Landefeld CS, Bero LA (2007). Characteristics and Impact of Drug Detailing for Gabapentin PLoS Medicine Vol. 4, No. 4, e134 doi:10.1371/journal.pmed.0040134
Visits from pharmaceutical representatives regarding gabapentin "detailing" were frequently followed by physician intentions to increase their future activity with the drug.
BMJ 2007;334:171 (27 January) US clinical guidelines often influenced by industry, NEJM says
Gøtzsche PC, Hróbjartsson A, Johansen HK, Haahr MT, Altman DG, et al. (2007) Ghost Authorship in Industry-Initiated Randomised Trials. PLoS Med 4(1): e19 doi:10.1371/journal.pmed.0040019
Transparency International. Global Corruption Report 2006. Corruption and Health
Die Deutsche Ausgabe ist nur über den Buchhandel erhältlich - s.a. Website Gesundheitswesen von TI.
Anders W Jørgensen, Jørgen Hilden, and Peter C Gøtzsche. BMJ 2006 333: 782 (14 October). Cochrane reviews compared with industry supported meta-analyses and other meta-analyses of the same drugs: systematic review. Industry supported reviews of drugs should be read with caution as they were less transparent, had few reservations about methodological limitations of the included trials, and had more favourable conclusions than the corresponding Cochrane reviews.
Catherine DeAngelis. The Influence of Money on Medical Science. JAMA. 2006;296:996-998
Richard Smith, Ian Roberts. Patient Safety Requires a New Way to Publish Clinical Trials. PLoS Clin Trials 1(1): e6. DOI: 10.1371/journal.pctr.0010006
s.a. Wissenschaftler-Protest: Die gegenwärtige Praxis der Publikation über klinische Studien gefährdet die Patientensicherheit
Richard Smith. Lapses at the New England Journal of Medicine. J R Soc Med 2006;99:380-382
Gøtzsche PC, Hróbjartsson A, Johansen HK, Haahr MT, Altman DG, Chan AW. Constraints on Publication Rights in Industry-Initiated Clinical Trials. JAMA. 2006;295:1645-1646
Patsopoulos NA, Analatos AA, Ioannidis JPA. Origin and funding of the most frequently cited papers in medicine: database analysis. BMJ 2006;332: 1061-3.
Cosgrove L, Krimsky S, Vijayaraghavan M, Schneider L. Financial Ties between DSM-IV Panel Members and the Pharmaceutical Industry Industry. Psychother Psychosom 2006;75(3):154-60.
Health
Industry Practices That Create Conflicts of Interest. T.A. Brennan, D.J.
Rothman, L. Blank, D. Blumenthal, S.C. Chimonas, J.J. Cohen, J. Goldman, J.P.
Kassirer, H. Kimball, J. Naughton and N. Smelser. JAMA 2006;295:429–433
25 January 2006
Meldung Deutsches
Ärzteblatt online 26.1.2006
Klemperer D. Vom Paternalismus zur Partnerschaft - Eine Profession im Wandel. in: Hurrelmann H (Hrsg.). Professionalisierung im Gesundheitswesen - Positionen - Potenziale - Perspektiven. Bern: Verlag Hans Huber, 2006, S.61-75. Download
Transparency International Deutschland. Transparenzmängel, Korruption und Betrug im deutschen Gesundheitswesen
Cash interests taint drug advice Nature 20 October 2005
Richard Smith. Curbing the Influence of the Drug Industry: A British View. PLoS September 2005.
A recent report from politicians in Britain recommends a fundamental review
of drug development, marketing, and prescribing practices
Scientists behaving badly. Nature, June 9, 2005
Academic Medical Centers' Standards for Clinical-Trial Agreements with Industry. NEJM, May 26, 2005
Richard Smith. Medical Journals Are an Extension of the Marketing Arm of Pharmaceutical Companies. PLoS May 17, 2005
House of Commons Health Committee. Fourth Report of Session 2004–05. The Influence of the
Pharmaceutical Industry.
Bericht einer Untersuchungskommission des Englischen Parlaments zum Einfluss
der Pharamzeutischen Industrie auf das Medizin- und Gesundheitssystem. Ein vergleichbarer
Bericht für Deutschland wäre wünschenswert.
Chimonas S, Rothman DJ. New federal guidelines for physician-pharmaceutical industry relationsthe politics of policy formation. Health Aff (Millwood) 2005;24:949-960
NIH and the U.S. Department of Health and Human Services Conflict of Interest Information and Resources
National Science and Engeneering Research Council of Canada Management of Federal Grants and Awards
David Blumenthal. Doctors and Drug Companies. NEJM. October 28, 2004
Ray Moynihan. Who pays for the pizza? Redefining the relationships between doctors and drug companies. 1: Entanglement
Ray Moynihan. Who pays for the pizza? Redefining the relationships between doctors and drug companies. 2: Disentanglement
Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 2003;326: 1167-70
Federal Policy on Research Misconduct.US Office of Science and Technology (OSTP).
grundlegendes Papier des amerikanischen Wissenschaftsministeriums
Derek Thompson. Understanding Financial Conflicts of Interest - grundlegender Aufsatz, insbesondere bezüglich der Definition von Interessenkonflikt
Marcia Angell. The Truth about the Drug Companies. How They Deceive Us and What to Do about It. Random House Trade, August 2005
Ray Moynihan, Alan Cassels. Selling Sickness: How Drug Companies Are Turning Us All into Patients. Allen & Unwin, September 2005
John Abramson. Overdosed America: The Broken Promise of American Medicine. Harper Perennial, Juni 2005
Deyo RA, Patrick DL. Hope or Hype. The Obsession with Medical Advances and the High Cost of False Promises. New York: Amacom, März 2005
Lundberg GD. Severed Trust. Why American Medicine Hasn't Been Fixed. Basic Books, 2000.
Robert B. Cialdini. Die Psychologie des Überzeugens. 5. Aufl. 2007. Verlag Hans Huber
NO FREE LUNCH "Just Say No to Drug Reps"i>
Transparency Deutschland - Gesundheitswesen
Institute on Medicine as a Profession
Inegrity in Science / Center for Science in the Public Interest
Research Integrity Bibliograpie. American Association for the Advancement of Science
Drug Promotion Database. Vom WHO Department of Essential Drugs & Medicines Policy und Health Action International Europe untertstützte Website mit Material zu den Fragen: What attitudes do people (professional and lay) have to promotion? What impact does pharmaceutical promotion have on attitudes and knowledge? What impact does pharmaceutical promotion have on behaviour? What interventions have been tried to counter promotional activities, and with what results?
Deutsche Gesundheitswissenschaftler und Tabakindustrie
Kleine Sammlung von Aufsätzen und Artikeln.
Interessenregister